
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings Inc. has demonstrated strong financial performance, with the oncology business achieving record quarterly revenue and a 10.3% increase in patient volumes, supported by improved revenue cycle collections. The company experienced a significant improvement in gross profit margin, rising 370 basis points to 55.2%, driven by revenue mix optimization and reduced pump disposal costs. With year-to-date net operating cash flow increasing by 38% to $17.3 million, and anticipated margin expansion due to enhancements in CRM systems and the growth of Wound Care and Pain Management segments, the outlook for InfuSystems remains positive.
Bears say
InfuSystems Holdings Inc. has faced a decline in gross margins, particularly within its Device Solutions division, which has negatively impacted overall financial performance alongside rising operational costs. Economic uncertainties have led to customer destocking, resulting in reduced demand and sales volumes, which have further pressured the company's margins. Additionally, estimates project FY26 revenue to remain flat at $143.6 million, indicating a stagnant growth outlook amid competitive headwinds and margin compression challenges.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares